NasdaqGM - Nasdaq Real Time Price ? USD Silexion Therapeutics Corp (SLXN) Follow Compare 0.3070 -0.0134 (-4.18%) At close: November 22 at 4:00 PM EST 0.2725 -0.03 (-11.24%) After hours: 7:58 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Silexion Therapeutics Announces 1-for-9 Reverse Share Split Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiativesGRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of i GlobeNewswire ? 5 hours ago SLXN -4.18% SLXNW Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida. Ilan Hadar, Chief Executive Officer will deliver a company presentation titled “Transformi GlobeNewswire ? 2 days ago SLXN -4.18% SLXNW Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications. GRAND CAYMAN, CAYMAN ISLANDS / ACCESSWIRE / November 14, 2024 / Silexion Therapeutics ... ACCESSWIRE ? 8 days ago SLXN -4.18% SLXNW Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit GRAND CAYMAN, CAYMAN ISLANDS / ACCESSWIRE / October 9, 2024 / Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its ... ACCESSWIRE ? last month SLXN -4.18% SLXNW Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies GRAND CAYMAN, Cayman Island, October 01, 2024--Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation. These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis Business Wire ? last month SLXN -4.18% SLXNW Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER? in Non-Resectable Pancreatic Cancer GRAND CAYMAN, Cayman Island, September 24, 2024--Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new findings from its Phase 2 trial of LODER? in patients with non-resectable locally advanced pancreatic cancer (LAPC) which bear the KRAS G12D or G12V mutation (approximately 70% of pancreatic cancer patients). Overall the updated analysis reveals a 56 Business Wire ? last month SLXN -4.18% SLXNW PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers LONDON, September 09, 2024--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion presents an interesting opportunity in the rapidly growing field of targeted cancer treatments, particularly in addressing the challenges of pancrea Business Wire ? 2 months ago SLXN -4.18% SLXNW Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. A company presentation will be available on demand here as of Monday, September 9 at 7:00 AM ET. Si GlobeNewswire ? 2 months ago SLXN -4.18% SLXNW Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business comb GlobeNewswire ? 3 months ago MACA MACAU MACAW Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return SLXN S&P 500 YTD -97.17% +25.15% 1-Year -97.17% +31.54% 3-Year -96.85% +27.06%
